Prostaglandin-endoperoxide synthase 2

Overview

Prostaglandin-endoperoxide synthase 2, encoded by the PTGS2 gene and commonly referred to as cyclooxygenase-2 (COX-2), is a bifunctional enzyme that catalyzes two sequential steps in the biosynthesis of prostaglandins from arachidonic acid: the cyclooxygenase reaction (converting arachidonic acid to prostaglandin G2) and the peroxidase reaction (reducing PGG2 to prostaglandin H2, or PGH2). PGH2 is then converted by downstream synthases into bioactive prostanoids including prostaglandin E2 (PGE2), thromboxanes, and prostacyclins. Unlike its constitutively expressed isoform COX-1 (PTGS1), COX-2 is an inducible enzyme whose expression is tightly regulated by pro-inflammatory stimuli, growth factors, cytokines such as interleukin-1 beta and interleukin-6, and transcription factors including nuclear factor kappa B (NF-κB) and MAPK signaling cascades. Its expression is normally low or absent in most tissues under homeostatic conditions but is rapidly upregulated in response to inflammatory, mitogenic, or oncogenic signals.

The pharmacological importance of PTGS2 is substantial. Non-steroidal anti-inflammatory drugs (NSAIDs) exert their analgesic and anti-inflammatory effects largely through inhibition of COX enzymes, and selective COX-2 inhibitors (coxibs)—including celecoxib, etoricoxib, and meloxicam—were developed to provide anti-inflammatory efficacy while reducing the gastrointestinal side effects associated with non-selective COX inhibition. Beyond inflammation and pain, PTGS2 is upregulated in a broad spectrum of cancers, where it promotes tumor growth, angiogenesis, immune evasion, and metastasis, partly through production of PGE2. This breadth of pathological relevance has established PTGS2 as one of the most extensively studied therapeutic targets in biomedicine.

Recent Publications Focus

Below is a summary of the newest research publications targeting Prostaglandin-endoperoxide synthase 2 (sorted by publication date).

Recent research on Prostaglandin-endoperoxide synthase 2 (COX-2/PTGS2) reflects a broad shift toward multi-target therapeutic strategies that leverage COX-2 inhibition as part of integrated treatment approaches. Network pharmacology studies have identified PTGS2 as a central hub gene in multiple disease contexts, including Alzheimer's disease, Clostridioides difficile infection, osteoarthritis, and chronic kidney disease. Rather than targeting COX-2 in isolation, contemporary research increasingly couples COX-2 inhibition with complementary mechanisms—such as dual targeting of c-Met and COX-2 for gastric and colorectal cancers, combined HDAC6/COX-2 inhibition for neurodegeneration, and integration of COX-2 suppression into multi-enzymatic inhibition strategies for anti-inflammatory and immunomodulatory effects.

A substantial body of work focuses on screening natural products and traditional herbal medicines as sources of COX-2 inhibitors. Studies have identified novel COX-2 inhibitory compounds from Yaobitong capsules, Curcumae Rhizoma (with alexandrin and hederagenin showing potent COX-2 binding affinity), Dendropanax proteus, Convolvulus oxyphyllus, Amomi Fructus Rotundus, and Erzhi Pills. These investigations employ integrated approaches combining liquid chromatography-mass spectrometry profiling, molecular docking, and network pharmacology to identify bioactive constituents, validate binding interactions with COX-2, and elucidate downstream inflammatory pathways. The molecular docking analyses consistently demonstrate strong ligand-target interactions, with binding affinities frequently comparable to or exceeding reference drugs such as celecoxib and Diclofenac sodium.

Synthetic chemistry efforts have produced novel COX-2-selective inhibitors with enhanced pharmacological profiles. Researchers have designed polyhydroxylated bis-chalcones, pyrimidine derivatives, thiadiazole derivatives, and 1,5-diarylpyrazole-based compounds that achieve selective COX-2 inhibition with reduced off-target effects and improved selectivity ratios. Mechanistic studies employing inhibitory kinetic analysis, molecular dynamics simulations, and structural biology have clarified how specific structural modifications (such as positional hydroxylation patterns and substituent placement) enhance COX-2 selectivity by restricting access to COX-1 active sites while establishing favorable interactions within COX-2 binding pockets.

The therapeutic mechanisms of COX-2 inhibition have been extensively characterized across multiple disease models. Suppression of PTGS2 expression leads to reduced prostaglandin E2 production and downstream anti-inflammatory effects, including decreased pro-inflammatory cytokine expression (IL-6, TNF-α, IL-1β), suppression of macrophage pro-inflammatory M1 polarization with concurrent enhancement of anti-inflammatory M2 macrophage phenotypes, and reduced oxidative stress and reactive oxygen species accumulation. In osteoarthritis, PROTAC-mediated protein degradation of COX-2 achieved near-complete clearance while simultaneously enhancing chondrocyte proliferation and suppressing apoptosis. In ischemic stroke and asthma models, COX-2 suppression attenuated neuroinflammation and airway inflammation respectively, with mechanistic studies revealing COX-2's involvement in regulatory pathways affecting ferroptosis, mitophagy, and immune cell polarization. Emerging evidence demonstrates that COX-2 inhibition can enhance immunotherapy efficacy—notably in post-operative tumor contexts where COX-2/PGE2 pathway suppression combined with immune checkpoint modulation substantially reduces tumor recurrence and metastasis, suggesting COX-2 as a key node in immunomodulatory cancer therapy.

Human pharmacokinetic studies, including bioequivalence evaluations of selective COX-2 inhibitors such as etoricoxib, continue to characterize the clinical pharmacology of this drug class. Additionally, emerging nano-formulation strategies encapsulating COX-2 inhibitors (including meloxicam and rosuvastatin-curcumin conjugates) demonstrate enhanced bioavailability, sustained release kinetics, and improved cellular uptake, positioning COX-2-targeted nanotherapeutics as a frontier for optimizing drug delivery and therapeutic efficacy in chronic inflammatory and neoplastic diseases.

Background PMIDs

[PMID 41864448]
[PMID 41932059]
[PMID 41982177]

Method PMIDs

[PMID 42371218]

Result PMIDs

[PMID 41576605]
[PMID 41619422]
[PMID 41663028]
[PMID 41734874]
[PMID 41795318]
[PMID 41849950]
[PMID 41894848]
[PMID 41894850]
[PMID 41924844]
[PMID 41988929]
[PMID 41997281]
[PMID 42119272]
[PMID 42184086]
[PMID 42219094]
[PMID 42361074]

Target PMIDs

[PMID 41579636]
[PMID 41621723]
[PMID 41633290]
[PMID 41638094]
[PMID 41780785]
[PMID 41785827]
[PMID 41797190]
[PMID 41806609]
[PMID 41812936]
[PMID 41861736]
[PMID 41865568]
[PMID 41879397]
[PMID 41879412]
[PMID 41905014]
[PMID 41918280]
[PMID 41921836]
[PMID 41924840]
[PMID 41924844]
[PMID 41982177]
[PMID 42035226]
[PMID 42048120]
[PMID 42081317]
[PMID 42102478]
[PMID 42128884]
[PMID 42140514]
[PMID 42214888]
[PMID 42230843]
[PMID 42301551]
[PMID 42336477]
[PMID 42365877]
[PMID 42393368]
[PMID 42406869]